Navigation Links
Study: Metformin for breast cancer less effective at higher glucose concentrations
Date:10/24/2013

A University of Colorado Cancer Center study published online this month in the journal Cell Cycle shows that breast cancer cell growth, motility and aggression is promoted by excess glucose, as experienced by patients with diabetes and metabolic syndrome. The study also showed that patients with high glucose may require higher doses of the drug metformin to achieve the same anti-cancer activity as patients with normal glucose levels.

Metformin, the most common first-line drug in the treatment of type-2 diabetes, has been shown in previous studies to reduce breast cancer risk, improve survival, and increase the effectiveness of chemotherapy. Numerous Phase III clinical trials are currently evaluating the benefits and best uses of metformin in breast cancer patients.

"We show that metformin works differently in high- compared to low-glucose conditions. Not only does it require a higher concentration of metformin to be active in high-glucose conditions, but we report that the drug regulates different genes within cancer cells at high as compared to normal glucose levels," says Ann Thor, MD, CU Cancer Center investigator, Todd Professor of Pathology at the University of Colorado School of Medicine, and the study's principal investigator.

The study evaluated the effects of metformin on 17 breast cancer cell lines representing each of the molecular subtypes of the disease, at varying glucose levels.

"Commonly, lab studies of metformin are performed with very high glucose concentrations about 17 millimols of glucose per liter. But the average glucose level in healthy humans is only about one third of that dose about 5 millimols per liter. And individuals with diabetes may have glucose at 10 millimols per liter. We wanted to study metformin activity under these conditions," Thor says.

So the question was this: how would metformin perform in breast cancer cells grown at more realistic, human levels of glucose?

"Results show that when you drop glucose down to human levels, metformin has an even bigger effect at standard doses. When glucose is high you need more metformin to achieve the same results," Thor says.

Thor also points out that skeptics of metformin treatment for cancer in general or breast cancer in particular frequently point to the high concentrations of metformin needed to create results in the laboratory.

"Our data helps to explain why higher doses of metformin are required to obtain anti-cancer effects when cancer cells are grown in the lab, as compared to its use in humans," Thor says.

Interestingly, "it wasn't simply that the metformin effectiveness went up as glucose came down, but that entirely new mechanisms of action were present at lower glucose levels," Thor says.

Specifically, Thor and colleagues used RNA expression arrays to discover which genes were affected by metformin at high and low glucose concentrations. At high glucose concentrations, metformin primarily affected genes involved in metabolic processes and cell proliferation; at low glucose concentrations, metformin affected genes controlling cellular process and programmed cell death.

In addition to affecting the growth of breast cancer cells, Thor and colleagues show the drug decreases the ability of breast cancer cells to move within the body a task necessary for the spread of the disease to other sites.

"An extension of this data implies that in breast cancer patients with diabetes or metabolic syndrome, metformin may less effective at the standard dose. To be effective, doctors may have to first explore glucose control or may have to use a higher dose of metformin," Thor says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Study: Death by moonlight? Not always
2. Study: Acidity can change cell membrane properties
3. Penn study: Shutting off neurons helps bullied mice overcome symptoms of depression
4. Rutgers study: Worms may shed light on human ability to handle chronic stress
5. UT study: Chemical in antibacterial soaps may harm nursing babies
6. Study: Pedometer program helps motivate participants to sit less, move more
7. Study: MicroRNA cooperation mutes breast cancer oncogenes
8. Study: Environmental policies matter for growing megacities
9. Study: Widespread test-and-treat HIV policies could increase dangerous drug resistance
10. Study: Probiotics reduce stress-induced intestinal flare-ups
11. Study: Antibiotics are unique assassins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... --  IdentyTechSolutions America LLC , a leading provider ... a cutting-edge manufacturer of software and hardware security ... integrated solutions that comprise IDT biometric readers and ... IdentyTech,s customers with combined physical identification and anti-tailgating ... theft. "We are proud to use ...
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
(Date:12/15/2016)... --  WaferGen Bio-systems, Inc. (NASDAQ: WGBS ... that on December 13, 2016, it received a letter ... Market LLC which acknowledged that, as of December 12, ... had been at $1.00 or greater for ten consecutive ... Rule 5550(a)(2) of the Nasdaq Stock Market. ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... YORK , Jan. 23, 2017  Today, the ... announce they have funded an important study that could ... prevent the onset of Alzheimer,s disease. This groundbreaking research ... Rockefeller University, led by Nobel Laureate Dr. Paul ... for Alzheimer,s disease. Fisher Center scientists have ...
(Date:1/23/2017)... Fl (PRWEB) , ... January 23, 2017 , ... ... venture-backed teleradiology and telemedicine company announces significant growth last year adding 65 new ... Veterans Authority and US Army medical centers as well as one of US ...
(Date:1/23/2017)... N.J. , Jan. 23, 2017   Enteris ... feasibility study agreement with Sanofi to leverage ... delivery platform, Peptelligence™, to develop an oral formulation of ... Joel Tune , Chief Executive Officer and Executive ... is further validation of the tremendous value our Peptelligence ...
(Date:1/23/2017)... Atlas Genetics Ltd., the ultra-rapid Point-Of-Care ... D financing, raising $35 million from a syndicate including all ... ... the Atlas Genetics io® system has been completed with the ... in February 2016.  This new Series D equity issue will ...
Breaking Biology Technology: